TLX101-Px (Pixlumi®) MAA Accepted in Europe

Telix Pharmaceuticals announced that its marketing authorization application (MAA) for TLX101-Px, an imaging candidate for glioma, has been accepted for review in Europe. The product aims to improve patient access to advanced brain imaging, helping to differentiate between tumor progression and treatment-related changes. The application is now in a 210-day assessment phase, with potential subsequent national marketing authorizations. TLX101-Px is positioned as a solution to significant unmet needs in the glioma imaging market, targeting L-type amino acid transporters. This step represents a milestone for Telix, supporting broader access to precision medicine in oncology.